Developer docs
API playgroundTry for free, no card

Search company profiles

ZAVA

Full company profile

uuid0000ksd

Namestring
ZAVA
Legal namestring
ZAVA
Company typeenum
Private
Founded yearint
2011
Descriptiontext

ZAVA is a pan-European direct-to-consumer telehealth platform founded in 2011 (originally as DrEd) and headquartered in Dublin, Ireland, with a UK regional office in London. The company serves individual patients across five European markets — the United Kingdom, Germany, France, Ireland, and Spain — by enabling online medical consultations via digital questionnaires that are reviewed by licensed, in-country physicians who issue digital prescriptions. Prescriptions are fulfilled either through a network of partner pharmacies (including 6,500 partner pharmacies in Germany) or via home delivery (Royal Mail in the UK, DHL in Germany), with typical doctor review times of under two hours in some markets. The platform is regulated by the UK GPhC and CQC, the Irish Medical Council, and corresponding authorities in Germany, France, and Spain, and holds LegitScript and ISO 27001 certifications.

ZAVA's product portfolio spans men's health (erectile dysfunction treatments such as Sildenafil and Tadalafil, hair loss treatments including Finasteride and Minoxidil, premature ejaculation), women's health and contraception (55+ contraceptive pill options, emergency contraception, bacterial vaginosis, cystitis, hormone replacement therapy), weight management (GLP-1 programs including Wegovy and Mounjaro with 200,000+ UK patients treated), sexual health (STI test kits and treatment for chlamydia, gonorrhoea, HIV, and herpes), chronic conditions (asthma, type 2 diabetes, cholesterol, hypertension, migraine, psoriasis), dermatology, fertility testing, and travel health (malaria prophylaxis, jet lag, traveler's diarrhea). Since inception, the platform has delivered 15+ million treatments and 7+ million consultations, with 1.3 million active customers and 2.3 million consultations completed in 2024.

ZAVA operates a pure direct-to-consumer transaction-based revenue model: patients pay per-consultation treatment fees (€12.90-€29.99 depending on country and treatment category) plus the cost of prescribed medication. The company is wholly owned by Hims & Hers Health, Inc. (NYSE:HIMS) following an all-cash acquisition announced in June 2025, which positioned ZAVA as the parent company's European platform for international expansion. Marketing is primarily organic — SEO, content marketing through physician-reviewed health articles, and patient referral — with regulatory exposure illustrated by the 2025 UK Advertising Standards Authority enforcement action banning affiliate-driven promotion of ZAVA's prescription weight-loss medicines.

Short descriptiontext

ZAVA is a pan-European direct-to-consumer telehealth platform founded in 2011, serving 1.3 million active patients across the UK, Germany, France, Ireland, and Spain with online doctor consultations, digital prescriptions, and medication delivery across 40+ conditions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
online doctor consultations, digital prescription services, telehealth platform, weight loss treatments, sexual health services
Industry3 codes
1Prescription-Based Digital Clinics (Condition-Specific Rx Programs)
CodeHLALAAADPrimaryYes
2Men’s Health Prescribing + Pharmacy Delivery Platforms
CodeHLALAIAJPrimaryNo
3Sexual & Pelvic Health Telehealth (STI care, pelvic pain, endometriosis/PCOS support)
CodeHLALAHAJPrimaryNo
NAICS code2 codes
  • Offices of Physicians6211
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Online Telehealth Services
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Online Consultation and Prescription Services
TypeTransaction Fee
Description

ZAVA generates revenue through direct-to-consumer online medical consultations where patients pay for a medical review and prescription service. The model is transaction-based with consultation fees plus medication costs. Services cover erectile dysfunction, hair loss, contraception, weight loss, and general health conditions.

zavamed.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Pricing details5 tiers
1Erectile dysfunction treatment consultation
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Medication price + €29.99 treatment fee. Example: Tadalafil from €12.58 + €29.99 fee, Sildenafil from €16.34 + €29.99 fee.

zavamed.com
2Hair loss treatment consultation
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Medication price + €19.99 treatment fee. Example: Finasterid 1mg from €26.60 + €19.99 fee, Propecia from €59.11 + €19.99 fee.

zavamed.com
3Contraceptive pill prescription
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Medication price + €12.90 treatment fee. Wide range of contraceptive pills from €17.55 + €12.90 fee.

zavamed.com
4Ireland prescription service
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Prescription service from €21.50

zavamed.com
5UK weight loss treatment
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Weight loss treatment starting from £99, no subscription, no hidden fees.

zavamed.com
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

ZAVA is a pan-European digital health platform that enables patients to consult licensed physicians online, receive diagnoses, and obtain prescriptions without face-to-face appointments. Patients complete a medical questionnaire, have it reviewed by a doctor, and receive digital prescriptions valid at local pharmacies or delivered to their home. The platform covers more than 40 conditions across men's health, women's health, sexual health, weight management, dermatology, and chronic conditions across the UK, Germany, France, Ireland, and Spain.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 15+ million treatments delivered since 2011
+2 more records
Product overview1 text field

ZAVA is a multi-country European digital health platform offering online doctor consultations and prescription services. The platform operates across Germany, France, Spain, Ireland, and the United Kingdom, providing treatments across men's health (erectile dysfunction, hair loss, premature ejaculation), women's health and contraception (55+ contraceptive options), weight loss (GLP-1 programs with Wegovy/Mounjaro), sexual health (STI testing and treatment), general health (asthma, diabetes, cholesterol, hypertension), skin conditions, and travel health. Patients complete a medical questionnaire online, receive doctor review, and obtain digital prescriptions for delivery or pharmacy pickup. The platform has completed over 15 million consultations since 2011.

Product and service9 records
1Online Doctor Consultation Platform
CategoryTelehealth consultation
Description

Digital health platform enabling patients to consult licensed doctors via online medical questionnaires, receive diagnoses, and obtain prescriptions without in-person visits, with pharmacy pickup or home delivery.

2Men's Health Treatments
3Women's Health and Contraception
CategoryWomen's health prescriptions
Description

Online prescription services for women's health including more than 55 contraceptive pill options, contraceptive rings, emergency contraception, bacterial vaginosis, cystitis, hormone replacement therapy, period delay, and thrush treatment.

4Weight Loss Treatment Program
CategoryWeight management prescriptions
Description

Doctor-supervised weight loss program offering GLP-1 agonists and other weight management medications including Wegovy and Mounjaro, with eligibility assessment based on BMI and medical history, ongoing clinical support, and follow-up.

5Sexual Health Services
CategorySexual health testing and treatment
Description

Online diagnosis, treatment, and home test kits for sexually transmitted infections including Chlamydia, Gonorrhoea, genital herpes, genital warts, trichomoniasis, HIV, Syphilis, and Hepatitis, with photo-based diagnosis and postal sample collection.

6General Health and Chronic Conditions
CategoryChronic condition prescriptions
Description

Online prescription renewals and treatments for chronic and general conditions including asthma, COPD, high blood pressure, type 2 diabetes, elevated cholesterol, migraine, psoriasis, hay fever, hyperhidrosis, smoking cessation, vitamin D deficiency, and heartburn.

7Fertility Testing
CategoryDiagnostic testing
Description

Male and female fertility test kits for home use, enabling patients to check hormone levels and reproductive health markers without visiting a clinic.

8Skin Conditions Treatment
CategoryDermatology prescriptions
Description

Online dermatology consultations and prescriptions for skin conditions including acne, eczema, rosacea, cold sores, perioral dermatitis, and psoriasis, with photo-based diagnosis available.

9Travel Health Services
CategoryTravel health prescriptions
Description

Online prescriptions for travel-related medications including malaria prophylaxis tablets, jet lag treatment, and traveler's diarrhoea medication.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-03
Description

Hims & Hers Health acquired ZAVA in an all-cash transaction to expand into European markets including UK, Germany, France, and Ireland. The acquisition was expected to close in H2 2025 and become accretive by 2026. ZAVA's 1.3 million active customers and 2.3 million consultations in 2024 supported Hims & Hers' international growth strategy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

NYSE-listed D2C telehealth platform offering prescription-based treatments for men's health, women's health, hair loss, weight loss, and mental health. ZAVA's parent company since 2025; closest direct competitor in business model and condition verticals, with US-focused execution.

TypeDirect peer
Description

UK-based online pharmacy and telehealth provider offering prescription medications and weight-loss treatments. Co-named with ZAVA in ASA advertising enforcement actions, indicating overlapping product mix and target customers in the British D2C telehealth market.

TypeDirect peer
Description

UK-based D2C men's health telehealth platform specializing in ED, hair loss, and weight loss. Directly competes with ZAVA in the UK on men's health conditions with similar online consultation + pharmacy delivery model.

TypeEmerging player
Description

US-based D2C telehealth platform offering prescription treatments for men's health, weight loss, and chronic conditions. Closely mirrors ZAVA's condition-specific Rx model but operates in the US market; relevant as a comparable business model reference.

TypeRegional player
Description

UK-based online GP consultation platform offering video appointments and prescriptions. Comparable business model in the UK market but focuses on general practice consultations rather than condition-specific Rx verticals like ZAVA.

TypeDirect peer
Description

UK online weight-loss clinic offering GLP-1 prescriptions. Co-named with ZAVA in ASA enforcement actions and directly competes in the UK weight-loss/GLP-1 vertical with similar digital consultation and home delivery model.

TypeDirect peer
Description

UK-based online pharmacy and telehealth provider offering prescription medications across men's health, women's health, and chronic conditions. Directly comparable D2C model and product portfolio to ZAVA in the UK and EU markets.

TypeRegional player
Description

France-based dominant healthcare booking and telehealth platform. While primarily an appointment-booking platform, Doctolib has expanded into video consultations and prescription services in France, overlapping with ZAVA's French market positioning.

TypeRegional player
Description

Swedish-origin digital healthcare platform operating across UK, France, Germany, and Nordics. Comparable pan-European telehealth footprint to ZAVA, though focused primarily on NHS/private GP video appointments rather than Rx-led condition-specific prescribing.

TypeDirect peer
Description

UK-based online pharmacy platform offering prescription medications including weight-loss treatments. Co-named with ZAVA in ASA enforcement; similar D2C model targeting UK patients seeking prescription medications without GP visits.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ZAVA

Online Telehealth Serviceszavamed.com

ZAVA is a pan-European direct-to-consumer telehealth platform founded in 2011, serving 1.3 million active patients across the UK, Germany, France, Ireland, and Spain with online doctor consultations, digital prescriptions, and medication delivery across 40+ conditions.

What ZAVA does

ZAVA is a pan-European direct-to-consumer telehealth platform founded in 2011 (originally as DrEd) and headquartered in Dublin, Ireland, with a UK regional office in London. The company serves individual patients across five European markets — the United Kingdom, Germany, France, Ireland, and Spain — by enabling online medical consultations via digital questionnaires that are reviewed by licensed, in-country physicians who issue digital prescriptions. Prescriptions are fulfilled either through a network of partner pharmacies (including 6,500 partner pharmacies in Germany) or via home delivery (Royal Mail in the UK, DHL in Germany), with typical doctor review times of under two hours in some markets. The platform is regulated by the UK GPhC and CQC, the Irish Medical Council, and corresponding authorities in Germany, France, and Spain, and holds LegitScript and ISO 27001 certifications.

ZAVA's product portfolio spans men's health (erectile dysfunction treatments such as Sildenafil and Tadalafil, hair loss treatments including Finasteride and Minoxidil, premature ejaculation), women's health and contraception (55+ contraceptive pill options, emergency contraception, bacterial vaginosis, cystitis, hormone replacement therapy), weight management (GLP-1 programs including Wegovy and Mounjaro with 200,000+ UK patients treated), sexual health (STI test kits and treatment for chlamydia, gonorrhoea, HIV, and herpes), chronic conditions (asthma, type 2 diabetes, cholesterol, hypertension, migraine, psoriasis), dermatology, fertility testing, and travel health (malaria prophylaxis, jet lag, traveler's diarrhea). Since inception, the platform has delivered 15+ million treatments and 7+ million consultations, with 1.3 million active customers and 2.3 million consultations completed in 2024.

ZAVA operates a pure direct-to-consumer transaction-based revenue model: patients pay per-consultation treatment fees (€12.90-€29.99 depending on country and treatment category) plus the cost of prescribed medication. The company is wholly owned by Hims & Hers Health, Inc. (NYSE:HIMS) following an all-cash acquisition announced in June 2025, which positioned ZAVA as the parent company's European platform for international expansion. Marketing is primarily organic — SEO, content marketing through physician-reviewed health articles, and patient referral — with regulatory exposure illustrated by the 2025 UK Advertising Standards Authority enforcement action banning affiliate-driven promotion of ZAVA's prescription weight-loss medicines.

ZAVA firmographics

Firmographics
Name
ZAVA
Legal name
ZAVA
Website
https://www.zavamed.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
101–250 employees
Short description
ZAVA is a pan-European direct-to-consumer telehealth platform founded in 2011, serving 1.3 million active patients across the UK, Germany, France, Ireland, and Spain with online doctor consultations, digital prescriptions, and medication delivery across 40+ conditions.
Ownership category
akta.pro rank

ZAVA industry classification

Industry
Product category
Online Telehealth Services
NAICS
Offices of Physicians (6211), Medical and Diagnostic Laboratories (62151)
SIC
Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro primary industry
Prescription-Based Digital Clinics (Condition-Specific Rx Programs) (HLALAAAD)
akta.pro secondary industries
Men’s Health Prescribing + Pharmacy Delivery Platforms (HLALAIAJ), Sexual & Pelvic Health Telehealth (STI care, pelvic pain, endometriosis/PCOS support) (HLALAHAJ)

Keywords

  • Online doctor consultations
  • Digital prescription services
  • Telehealth platform
  • Weight loss treatments
  • Sexual health services

Where ZAVA is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices2 records

Markets served

ZAVA business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Online Consultation and Prescription Services: ZAVA generates revenue through direct-to-consumer online medical consultations where patients pay for a medical review and prescription service. The model is transaction-based with consultation fees plus medication costs. Services cover erectile dysfunction, hair loss, contraception, weight loss, and general health conditions.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goErectile dysfunction treatment consultation
Unit PricingPay-as-you-goHair loss treatment consultation
Unit PricingPay-as-you-goContraceptive pill prescription
Unit PricingPay-as-you-goIreland prescription service
Unit PricingPay-as-you-goUK weight loss treatment

Go-to-market motion1 record

Distribution channels5 records

Marketing channels3 records

ZAVA product offering

Product offering

Core offering

ZAVA is a pan-European digital health platform that enables patients to consult licensed physicians online, receive diagnoses, and obtain prescriptions without face-to-face appointments. Patients complete a medical questionnaire, have it reviewed by a doctor, and receive digital prescriptions valid at local pharmacies or delivered to their home. The platform covers more than 40 conditions across men's health, women's health, sexual health, weight management, dermatology, and chronic conditions across the UK, Germany, France, Ireland, and Spain.

Product overview

ZAVA is a multi-country European digital health platform offering online doctor consultations and prescription services. The platform operates across Germany, France, Spain, Ireland, and the United Kingdom, providing treatments across men's health (erectile dysfunction, hair loss, premature ejaculation), women's health and contraception (55+ contraceptive options), weight loss (GLP-1 programs with Wegovy/Mounjaro), sexual health (STI testing and treatment), general health (asthma, diabetes, cholesterol, hypertension), skin conditions, and travel health. Patients complete a medical questionnaire online, receive doctor review, and obtain digital prescriptions for delivery or pharmacy pickup. The platform has completed over 15 million consultations since 2011.

Differentiator

Problem solved

Functional benefit

Products and services

  • Online Doctor Consultation Platform Digital health platform enabling patients to consult licensed doctors via online medical questionnaires, receive diagnoses, and obtain prescriptions without in-person visits, with pharmacy pickup or home delivery.
  • Men's Health Treatments
  • Women's Health and Contraception Online prescription services for women's health including more than 55 contraceptive pill options, contraceptive rings, emergency contraception, bacterial vaginosis, cystitis, hormone replacement therapy, period delay, and thrush treatment.
  • Weight Loss Treatment Program Doctor-supervised weight loss program offering GLP-1 agonists and other weight management medications including Wegovy and Mounjaro, with eligibility assessment based on BMI and medical history, ongoing clinical support, and follow-up.
  • Sexual Health Services Online diagnosis, treatment, and home test kits for sexually transmitted infections including Chlamydia, Gonorrhoea, genital herpes, genital warts, trichomoniasis, HIV, Syphilis, and Hepatitis, with photo-based diagnosis and postal sample collection.
  • General Health and Chronic Conditions Online prescription renewals and treatments for chronic and general conditions including asthma, COPD, high blood pressure, type 2 diabetes, elevated cholesterol, migraine, psoriasis, hay fever, hyperhidrosis, smoking cessation, vitamin D deficiency, and heartburn.
  • Fertility Testing Male and female fertility test kits for home use, enabling patients to check hormone levels and reproductive health markers without visiting a clinic.
  • Skin Conditions Treatment Online dermatology consultations and prescriptions for skin conditions including acne, eczema, rosacea, cold sores, perioral dermatitis, and psoriasis, with photo-based diagnosis available.
  • Travel Health Services Online prescriptions for travel-related medications including malaria prophylaxis tablets, jet lag treatment, and traveler's diarrhoea medication.

Quantifiable outcome

  • 15+ million treatments delivered since 2011
  • +2 more outcomes

Companies that use ZAVA

Customer profile

Segments2 records

Ideal customer profiles2 records

ZAVA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

ZAVA partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Hims & Hers HealthcoreStrategic or Co-development Partner · 3 June 2025Hims & Hers Health acquired ZAVA in an all-cash transaction to expand into European markets including UK, Germany, France, and Ireland. The acquisition was expected to close in H2 2025 and become accretive by 2026. ZAVA's 1.3 million active customers and 2.3 million consultations in 2024 supported Hims & Hers' international growth strategy.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

ZAVA competitors and assessment

Company assessment

Direct peers

  • Hims & Hers Health: NYSE-listed D2C telehealth platform offering prescription-based treatments for men's health, women's health, hair loss, weight loss, and mental health. ZAVA's parent company since 2025; closest direct competitor in business model and condition verticals, with US-focused execution.
  • MedExpress: UK-based online pharmacy and telehealth provider offering prescription medications and weight-loss treatments. Co-named with ZAVA in ASA advertising enforcement actions, indicating overlapping product mix and target customers in the British D2C telehealth market.
  • Numan: UK-based D2C men's health telehealth platform specializing in ED, hair loss, and weight loss. Directly competes with ZAVA in the UK on men's health conditions with similar online consultation + pharmacy delivery model.
  • Voy: UK online weight-loss clinic offering GLP-1 prescriptions. Co-named with ZAVA in ASA enforcement actions and directly competes in the UK weight-loss/GLP-1 vertical with similar digital consultation and home delivery model.
  • Treated: UK-based online pharmacy and telehealth provider offering prescription medications across men's health, women's health, and chronic conditions. Directly comparable D2C model and product portfolio to ZAVA in the UK and EU markets.
  • UK Meds Direct: UK-based online pharmacy platform offering prescription medications including weight-loss treatments. Co-named with ZAVA in ASA enforcement; similar D2C model targeting UK patients seeking prescription medications without GP visits.

Emerging players

  • Ro (Roman): US-based D2C telehealth platform offering prescription treatments for men's health, weight loss, and chronic conditions. Closely mirrors ZAVA's condition-specific Rx model but operates in the US market; relevant as a comparable business model reference.

Regional players

  • Push Doctor: UK-based online GP consultation platform offering video appointments and prescriptions. Comparable business model in the UK market but focuses on general practice consultations rather than condition-specific Rx verticals like ZAVA.
  • Doctolib: France-based dominant healthcare booking and telehealth platform. While primarily an appointment-booking platform, Doctolib has expanded into video consultations and prescription services in France, overlapping with ZAVA's French market positioning.
  • Kry / Livi: Swedish-origin digital healthcare platform operating across UK, France, Germany, and Nordics. Comparable pan-European telehealth footprint to ZAVA, though focused primarily on NHS/private GP video appointments rather than Rx-led condition-specific prescribing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

ZAVA social profiles

Digital presence

ZAVA compliance and trust

Trust signal

Compliance6 records

ZAVA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ZAVA leadership team

Management profile

Number of profiles

Profiles8 records

ZAVA funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ZAVA M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZAVA

What does ZAVA do?

ZAVA is a pan-European digital health platform that enables patients to consult licensed physicians online, receive diagnoses, and obtain prescriptions without face-to-face appointments. Patients complete a medical questionnaire, have it reviewed by a doctor, and receive digital prescriptions valid at local pharmacies or delivered to their home. The platform covers more than 40 conditions across men's health, women's health, sexual health, weight management, dermatology, and chronic conditions across the UK, Germany, France, Ireland, and Spain.

Is ZAVA a public or private company?

ZAVA is a private company. It is classified as corporate owned and is currently operating.

When was ZAVA founded?

ZAVA was founded in 2011. It employs 101 to 250 people.

Where is ZAVA based?

ZAVA is headquartered in Dublin, Ireland, in the Europe region.

How does ZAVA make money?

One revenue line is on record: online Consultation and Prescription Services.

Who are ZAVA's main competitors?

Direct peers on record are Hims & Hers Health, MedExpress, Numan, Voy, Treated and UK Meds Direct. Ro (Roman) is listed as an emerging player. Regional players are Push Doctor, Doctolib and Kry / Livi.

Does ZAVA have an API?

No public API is recorded for ZAVA.

What industry is ZAVA in?

ZAVA's product category is Online Telehealth Services. Its primary akta.pro industry code is HLALAAAD, Prescription-Based Digital Clinics (Condition-Specific Rx Programs), with a secondary code of HLALAIAJ, Men’s Health Prescribing + Pharmacy Delivery Platforms. Its NAICS code is 6211 and its SIC code is 8011.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewHIMS Stock Dips 14.3% Since Q1 Earnings: Should You Still Hold or Sell?Hims & Hers Health, Inc. reported first-quarter 2026 results on May 11, 2026, posting modest revenue growth but a net loss compared to prior-year profitability, with gross margins contracting due to restructuring charges and elevated operating expenses. The company's stock declined 14.3% since the earnings release, underperforming both the sector and the S&P 500, despite a 48.7% gain over the past three months. The company reaffirmed revenue guidance of $680-$700 million for Q2 2026 and $2.8-$3 billion for the full year, and continues expanding its healthcare ecosystem through a collaboration with Novo Nordisk on GLP-1 weight loss treatments and international acquisitions of ZAVA, Livewell and Eucalyptus.The Motley FoolHims & Hers Stock Drops After Earnings: Buying Opportunity or Warning Sign?Hims & Hers reported Q1 2026 revenue of $608.1 million, up 4% year over year, but posted a net loss of $92.1 million and adjusted EBITDA fell to $44.3 million. Shares dropped over 12% after the release, with management raising full-year revenue guidance but cutting adjusted EBITDA guidance. The company continues generating positive free cash flow and expanding internationally.TradingViewCan Platform Expansion Support Hims & Hers Stock Before Q1 Earnings?Hims & Hers Health, Inc. is scheduled to report first-quarter 2026 earnings on May 11, with Zacks consensus estimates projecting revenue of $619.6 million (up 5.7% year-over-year) and EPS of 4 cents (down 80% year-over-year). The company's platform expansion into weight-loss treatments through its Novo Nordisk collaboration, new specialty offerings including testosterone therapy and menopause care, and international growth following the ZAVA and Livewell acquisitions are expected to drive performance, though elevated operating expenses and regulatory uncertainty around compounded GLP-1 products may pressure profitability. Hims & Hers also announced a proposed acquisition of Eucalyptus to further expand its international footprint across Europe, Canada, Australia, and Japan.Pharmaceutical TechnologyBritish patients risking “fake” weight loss drugs, despite safety concerns, survey says - Pharmaceutical TechnologyA Zava survey of 1,004 UK patients found 21% took weight loss drugs without a prescription, with 11.75% buying from social media. 22% suspect illegitimacy but still use them, as regulators warn of counterfeit risks. The illicit trade is growing amid rising prescription costs and shortages.Evening StandardSocial media ads for prescription-only weight-loss medicines bannedThe UK's Advertising Standards Authority (ASA) banned the first social media posts by members of the public promoting prescription-only weight-loss medicines including Mounjaro through affiliate and referral schemes for online pharmacies Voy, Zava, MedExpress, and UK Meds Direct. The regulator ruled that both brands and individuals are responsible for advertising rules, and that posts featuring affiliate links count as advertisements even when shared on personal social media accounts. The ASA stated this is a priority enforcement area because promoting these powerful prescription medicines irresponsibly can put people at serious risk.The IndependentSocial media ads for prescription-only weight-loss medicines bannedThe Advertising Standards Authority (ASA) has banned social media posts by members of the public that advertised prescription-only weight-loss medicines, including Mounjaro, through affiliate and referral schemes on Instagram, TikTok, and Facebook. The posts, which offered discount codes and referral links, were found to be illegal advertising as they promoted prescription medicines to the general public without proper regulatory oversight. Online pharmacies Voy, Zava, MedExpress, and UK Meds Direct were found responsible for ensuring their affiliate schemes did not circumvent advertising rules.MarketScreenerHims and Hers to offer weight-loss treatments in UKHims and Hers Health is launching weight-loss membership and treatment plans in the United Kingdom, including Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, at a starting price of 149 pounds per month. The company, which acquired London-based Zava earlier this year to facilitate the expansion, is replicating its U.S. subscription-based telehealth model in the UK market. Prices for GLP-1 drugs in the UK are substantially lower than U.S. prices, where Lilly's Zepbound ranges from $299 to $449 monthly and Novo's Wegovy costs $199 to $349.YahooHims & Hers Expands Care Scope as Digital Health Platforms EvolveHims & Hers Health expanded its clinical portfolio in 2025 with new offerings for low testosterone and menopause, while planning international growth through the acquisition of ZAVA in Europe and expansion into Canada. Concurrently, Tempus AI advanced its precision health capabilities by securing FDA clearance for diagnostic tools and acquiring Paige to enhance its digital pathology AI. Medifast also deepened its focus on metabolic health by launching new nutrition products and GLP-1 companion programs supported by LifeMD clinicians.The SunThe 6 sex positions that tone your whole body while enjoying some saucy action, you don’t have to be a gymnast for themOnline healthcare provider ZAVA, through its medical advisor Dr. Crystal Wyllie, has identified six sexual positions that engage various muscle groups and burn calories as an alternative to traditional gym workouts. The report details specific calorie expenditure estimates for both men and women across positions such as missionary, cowgirl, and standing, suggesting these activities can aid in weight management and physical toning.TradingViewHims & Hers Expands AI-Driven Personalized and Subscription-Based CareHims & Hers is expanding its AI-driven, subscription-based care model globally, including a planned Canadian entry and acquisition of ZAVA. The company completed an $870 million convertible notes offering to fund expansion. Shares have gained 71.7% year to date, with a forward P/S of 3.4X.